Posted by Michael Wonder on 24 Oct 2022
European Medicines Agency grants PRIME designation to BIT Pharma’s NicaPlant for treatment of non-traumatic subarachnoid haemorrhage in patients undergoing surgery.
19 October 2022 - BIT Pharma today announced that the EMA has granted access to the Priority Medicines (PRIME) scheme for NicaPlant, a novel, modified release implant for the treatment of non-traumatic subarachnoid haemorrhage in patients undergoing surgery.
NicaPlant was designated as an orphan medicine by EMA during its development already in 2019.
